Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications

  • Sarepta Therapeutics Inc SRPT will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone promises.
  • Under the agreement, Sarepta will have the rights to five neuromuscular and cardiac indications, including Duchenne muscular dystrophy.
  • According to Sarepta, the deal covers the MyoAAV program that aims to deliver more efficient gene therapies and at lower doses using modified capsids. 
  • Also Read: Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts.
  • Delivered 25-50 times greater gene expression in multiple skeletal muscles and 10-15 times greater gene expression in cardiac muscle;
  • Demonstrated reduced delivery to the liver by 50% and showed lower accumulation in the liver.
  • Due to increased efficiency, it can be used at up to a log lower dose than traditional AAV vectors.
  • Full research for MyoAAV in a Duchenne mouse model was published in Cell in 2021. Sarepta CEO Doug Ingram said the viruses could "substantially reduce viral load," while CSO Louise Rodino-Klapac touted the platform's "broad applicability."
  • Price Action: SRPT shares are up 3.17% at $109.38 during the market session on the last check Monday.
Loading...
Loading...
SRPT Logo
SRPTSarepta Therapeutics Inc
$60.85-1.07%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
7.82
Growth
-
Quality
-
Value
57.90
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...